163 related articles for article (PubMed ID: 8662098)
21. [Isotopic scan with somatostatin receptors in a case of recurrent carcinoid tumor. Relevance of tomographic detection].
Bernà Roqueta L; Martín Marimón JC; Martín Martínez J
Rev Esp Med Nucl; 2002 Apr; 21(2):123-4. PubMed ID: 11879622
[No Abstract] [Full Text] [Related]
22. [Scintigraphy of somatostatin receptors in the diagnosis and staging of neuroendocrine tumors of the digestive tract and pancreas].
Banzo J; Abós MD; Prats E; García F; Razola P
Rev Esp Med Nucl; 2000 Jun; 19(3):225-41. PubMed ID: 11062088
[No Abstract] [Full Text] [Related]
23. Somatostatin receptor scintigraphy (SRS): a new diagnostic tool in neuroblastoma (NB)?
Dörr U; Sautter-Bihl ML; Schilling FH; Koscielniak E; Treuner J; Bihl H
Prog Clin Biol Res; 1994; 385():355-61. PubMed ID: 7972231
[No Abstract] [Full Text] [Related]
24. Somatostatin receptor scintigraphy of malignant somatostatinoma with indium-111-pentetreotide.
Schillaci O; Annibale B; Scopinaro F; delle Fave G; Colella AC
J Nucl Med; 1997 Jun; 38(6):886-7. PubMed ID: 9189135
[TBL] [Abstract][Full Text] [Related]
25. [111-indium DTPA octreotide scintigraphy in colorectal liver metastases].
Seifert JK; Görges R; Bockisch A; Junginger T
Langenbecks Arch Chir; 1997; 382(6):332-6. PubMed ID: 9498205
[TBL] [Abstract][Full Text] [Related]
26. [Somatostatin receptor scintigraphy in endocrine orbitopathy].
Diaz M; Kahaly G; Mühlbach A; Bockisch A; Beyer J; Hahn K
Rofo; 1994 Dec; 161(6):484-8. PubMed ID: 7803769
[TBL] [Abstract][Full Text] [Related]
27. Somatostatin receptor scintigraphy in forty-eight patients with the Zollinger-Ellison syndrome. GRESZE: Groupe d'Etude du Syndrome de Zollinger-Ellison.
de Kerviler E; Cadiot G; Lebtahi R; Faraggi M; Le Guludec D; Mignon M
Eur J Nucl Med; 1994 Nov; 21(11):1191-7. PubMed ID: 7859770
[TBL] [Abstract][Full Text] [Related]
28. A new radiolabelled somatostatin analogue [111In-DTPA-D-Phe1]RC-160: preparation, biological activity, receptor scintigraphy in rats and comparison with [111In-DTPA-D-Phe1]octreotide.
Breeman WA; Hofland LJ; van der Pluijm M; van Koetsveld PM; de Jong M; Setyono-Han B; Bakker WH; Kwekkeboom DJ; Visser TJ; Lamberts SW
Eur J Nucl Med; 1994 Apr; 21(4):328-35. PubMed ID: 7911760
[TBL] [Abstract][Full Text] [Related]
29. Somatostatin receptor scintigraphy and octreotide treatment in patients with thyroid eye disease.
Krassas GE; Dumas A; Pontikides N; Kaltsas T
Clin Endocrinol (Oxf); 1995 Jun; 42(6):571-80. PubMed ID: 7634496
[TBL] [Abstract][Full Text] [Related]
30. Somatostatin receptor imaging: current status and future perspectives.
Bohuslavizki KH
J Nucl Med; 2001 Jul; 42(7):1057-8. PubMed ID: 11438628
[No Abstract] [Full Text] [Related]
31. Somatostatin receptor scintigraphy in brain tumors and pituitary tumors: first experiences.
Scheidhauer K; Hildebrandt G; Luyken C; Schomäcker K; Klug N; Schicha H
Horm Metab Res Suppl; 1993; 27():59-62. PubMed ID: 8330874
[TBL] [Abstract][Full Text] [Related]
32. True positive somatostatin receptor scintigraphy in primary breast cancer correlates with expression of sst2A and sst5.
Schulz S; Helmholz T; Schmitt J; Franke K; Otto HJ; Weise W
Breast Cancer Res Treat; 2002 Apr; 72(3):221-6. PubMed ID: 12058963
[TBL] [Abstract][Full Text] [Related]
33. Metastasis of neuroendocrine colon carcinoma mimicking Graves' ophthalmopathy.
Busse F; Führer D; Stumvoll M; Schneider JP; Neid M; Kluge R; Sterker I
Thyroid; 2008 Nov; 18(11):1237-8. PubMed ID: 18925841
[No Abstract] [Full Text] [Related]
34. Cost-effectiveness analysis of somatostatin receptor scintigraphy.
Kwekkeboom DJ; Lamberts SW; Habbema JD; Krenning EP
J Nucl Med; 1996 Jun; 37(6):886-92. PubMed ID: 8683305
[TBL] [Abstract][Full Text] [Related]
35. Receptor scintigraphy with 111In-pentetreotide for endocrine gastroenteropancreatic tumors.
Joseph K; Stapp J; Reinecke J; Skamel HJ; Höffken H; Neuhaus C; Lenze H; Trautmann ME; Arnold R
Horm Metab Res Suppl; 1993; 27():28-35. PubMed ID: 8330869
[TBL] [Abstract][Full Text] [Related]
36. Use of an isotopic somatostatin receptor probe to image gut endocrine tumors.
Modlin IM; Cornelius E; Lawton GP
Arch Surg; 1995 Apr; 130(4):367-73; discussion 373-4. PubMed ID: 7710334
[TBL] [Abstract][Full Text] [Related]
37. Somatostatin receptor expression in Hürthle cell cancer of the thyroid.
Gulec SA; Serafini AN; Sridhar KS; Peker KR; Gupta A; Goodwin WJ; Sfakianakis GN; Moffat FL
J Nucl Med; 1998 Feb; 39(2):243-5. PubMed ID: 9476928
[TBL] [Abstract][Full Text] [Related]
38. Radiolabeled octreotide for the demonstration of somatostatin receptors in malignant lymphoma and lymphadenopathy.
Lipp RW; Silly H; Ranner G; Dobnig H; Passath A; Leb G; Krejs GJ
J Nucl Med; 1995 Jan; 36(1):13-8. PubMed ID: 7799065
[TBL] [Abstract][Full Text] [Related]
39. Somatostatin receptor scintigraphy in central nervous system tumors: role of blood-brain barrier permeability.
Haldemann AR; Rösler H; Barth A; Waser B; Geiger L; Godoy N; Markwalder RV; Seiler RW; Sulzer M; Reubi JC
J Nucl Med; 1995 Mar; 36(3):403-10. PubMed ID: 7884502
[TBL] [Abstract][Full Text] [Related]
40. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
